Skip to main content

Table 4 Characteristics and medical costs of patients with 12 month-follow-up period pre- and post-BT initiation

From: Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

 

Total

BT-naïve

ADL

IFX

UST

Sub

total

ADL

IFX

UST

Subtotal

Number of patients

18

20

37

77

14

19

30

64

Average Age

47.7

46.5

46.2

46.8

49.6

47.3

46.3

47.5

%Female

11.1%

20.0%

16.2%

15.6%

14.3%

21.1%

20.0%

18.8%

Cost (pre)

¥760

¥950

¥900

¥886

¥365

¥916

¥603

¥641

In 1000

JPY unit

IP

¥18

¥343

¥254

¥235

¥0

¥361

¥162

¥188

OP

¥513

¥301

¥425

¥405

¥133

¥261

¥216

¥210

RX

¥229

¥306

¥221

¥246

¥232

¥294

¥225

¥244

Cost increase

¥1538

¥2429

¥1865

¥1907

¥1853

¥2494

¥2221

¥2187

In 1000

JPY unit

IP

¥95

¥601

- ¥37

¥156

¥146

¥633

¥21

¥228

OP

¥1077

¥1958

¥2011

¥1754

¥1379

¥1974

¥2296

¥1965

RX

¥366

- ¥130

- ¥109

- ¥2

¥328

- ¥113

- ¥96

- ¥5

  1. ADL Adalimumab, IFX Infliximab, UST Ustekinumab, pre:12 months pre-initiation, cost increase: increase from pre to post 12 months post-initiation, JPY Japanese Yen, IP inpatient medical costs, OP outpatient medical cost, RX costs of drugs other than BTs